Atea Pharmaceuticals disclosed preclinical findings demonstrating that its investigational compound AT-587 exhibits significant antiviral activity against Hepatitis E Virus (HEV), positioning the asset as a potential first-in-class therapeutic option. According to data presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026, AT-587 and the companion molecule AT-2490 demonstrated potency levels 30 to 150 times greater than existing agents sofosbuvir and ribavirin in laboratory testing.
The preclinical results underscore a notable gap in current treatment options, as no antivirals have received regulatory approval specifically for HEV infection despite the virus's global health implications. Atea indicated its intention to advance AT-587 into human testing, with Phase 1 clinical trials expected to commence in mid-2026, marking a pivotal step toward potentially addressing this unmet medical need.
The progression to clinical development represents a significant milestone for the company's virology pipeline and could establish a new standard of care for HEV patients if efficacy and safety are confirmed in human studies.